Attached files
| file | filename |
|---|---|
| EX-31.2 - EX-31.2 - Unity Biotechnology, Inc. | ubx-ex312_8.htm |
| EX-31.1 - EX-31.1 - Unity Biotechnology, Inc. | ubx-ex311_9.htm |
| 10-Q - 10-Q - Unity Biotechnology, Inc. | ubx-10q_20180331.htm |
Exhibit 32.1
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Quarterly Report of Unity Biotechnology, Inc. (the “Company”) on Form 10-Q for the period ending March 31, 2018 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:
|
|
(1) |
The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and |
|
|
(2) |
The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company. |
|
Date: June 7, 2018 |
|
By: |
/s/ Keith R. Leonard Jr. |
|
|
|
|
Keith R. Leonard Jr. |
|
|
|
|
Chairman and Chief Executive Officer (Principal Executive Officer) |
|
Date: June 7, 2018 |
|
By: |
/s/ Robert C. Goeltz II |
|
|
|
|
Robert C. Goeltz II |
|
|
|
|
Chief Financial Officer (Principal Financial Officer) |